Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses

Supernus Pharmaceuticals reported mixed Q2 2025 earnings, with revenue of $165 million significantly surpassing forecasts by 7.26%, driven by strong growth in key products like KELBRE and GOCOVRI and the recent acquisition of Sage Therapeutics. Despite an earnings per share (EPS) miss at $0.40 against an expected $0.48, the company's shares rose 1.3% in after-hours trading, reflecting investor optimism fueled by a raised full-year revenue guidance to $670-$700 million and a robust balance sheet, setting the stage for accelerated growth in CNS and women's health markets.

Analysis

Supernus Pharmaceuticals (SUPN) presented a mixed Q2 2025 financial report, characterized by a significant revenue beat and a notable earnings per share (EPS) miss. The company generated $165 million in revenue, exceeding the $154.3 million forecast by 7.26%, while its EPS of $0.40 fell 16.67% short of the anticipated $0.48. The market's positive reaction, with a 1.3% after-hours stock increase, suggests investors are prioritizing the firm's strategic execution and top-line momentum over the earnings shortfall. This momentum is driven by the successful transition away from legacy products; excluding these, revenue grew 17% year-over-year. Core growth drivers performed robustly, with KELBRE prescriptions up 23% and GOCOVRI prescriptions up 14%. The recent acquisition of Sage Therapeutics and its product ZERZUVE, which is showing strong early traction with 68% quarter-over-quarter revenue growth, marks a pivotal expansion into the women's health market. This strategic move, combined with strong organic performance, prompted management to raise full-year revenue guidance to a range of $670-$700 million. Financially, Supernus maintains a formidable balance sheet with $523 million in cash (pre-acquisition), a debt-to-equity ratio of just 0.03, and no debt, providing significant flexibility for future M&A even after the Sage deal.

Key Decisions for Investors

• Investors should look beyond the headline EPS miss and focus on the 17% year-over-year revenue growth from core products, as this indicates a successful strategic pivot and strong underlying operational health.
• The acquisition of Sage Therapeutics introduces significant growth potential via ZERZUVE but also integration risk; monitor ZERZUVE's sales trajectory and management's execution on integrating the new OBGYN-focused commercial efforts.
• Note the updated full-year guidance, which projects a GAAP operating loss of $70-$80 million due to acquisition costs, making the non-GAAP operating earnings forecast of $105-$135 million a more relevant metric for assessing core profitability in the near term.
• Given the stock is trading near its 52-week high, the positive outlook may be partially priced in, but continued strong performance from new launches like Anatco and upward analyst revisions could provide further catalysts for appreciation.